|
Volumn 162, Issue 5, 2015, Pages 937-
|
PD-1 Blockers
|
Author keywords
[No Author keywords available]
|
Indexed keywords
NIVOLUMAB;
PEMBROLIZUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
PROGRAMMED DEATH 1 RECEPTOR;
CANCER CHEMOTHERAPY;
DRUG EFFICACY;
HUMAN;
IMMUNE RESPONSE;
METASTATIC MELANOMA;
NON SMALL CELL LUNG CANCER;
NOTE;
PRIORITY JOURNAL;
TREATMENT INDICATION;
ANTAGONISTS AND INHIBITORS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIAL (TOPIC);
LUNG NEOPLASMS;
MELANOMA;
SKIN NEOPLASMS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS AS TOPIC;
HUMANS;
LUNG NEOPLASMS;
MELANOMA;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SKIN NEOPLASMS;
|
EID: 84940403833
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2015.07.045 Document Type: Short Survey |
Times cited : (124)
|
References (9)
|